Quest Diagnostics

DGX

Market cap $21.7B

Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here is how Quest Diagnostics (DGX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

SECAUCUS, N.J., May 19, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on July 22, 2026 to shareholders of record of Quest Diagnostics common stock on July 8, 2026.

Quest Diagnostics gains from DIS growth, advanced diagnostics uptake and AI-driven efficiencies, though debt levels and healthcare reimbursement risks remain concerns.

Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.

Guidance upgrades are generally among the most bullish announcements a company can make, signaling that the outlook is even better than previously expected.

Quest Diagnostics delivered strong Q1 results with 9.2% revenue growth and 13% EPS growth, driving management to raise 2026 guidance. DGX's growth is fueled by advanced diagnostics, robust consumer and hospital channels, and efficiency gains from AI and automation. Key risks include margin pressure from lower-priced partnership volumes and potential Medicare reimbursement cuts under PAMA.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.